StreetAlpha
13F holdings · Q3 2026

Vestal Point Capital

New York, NY · files as Vestal Point Capital, LP
Know the moment Vestal Point Capital filesYou follow Vestal Point Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1974915

Vestal Point Capital reported 63 stocks worth $3.9B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ABVX (10.1%), NBIX (9.2%) and BMRN (8.6%). Compared with Q2 2026, the fund opened new positions in TVTX, RCUS and BBIO, added to ABVX, NBIX and ARWR, trimmed BMRN, NRIX and ELVN and sold out of ABT, AZN and RVMD.

Latest filing: what Vestal Point Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
15 new23 added20 trimmed20 sold outBought about $1.3B · sold about $1.2B
New 15
See all 15 →
Added 23
See all 23 →
Trimmed 20
  • ZBH−$82.2M−66%
  • PODD−$64.6M−74%
  • SNY−$61.8M−75%
  • ELVN−$35.5M−19%
  • BMRN−$30M−8%
See all 20 →
Sold out 20
See all 20 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$3.9B−9.6% vs last quarter
Stocks held6315 new · 20 sold out
Top 5 weight44.0%fairly concentrated
Turnover65%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ABVX
Abivax SA
$392M10.1%4M+1.6M (+69%)5 of 8
2
NBIX
Neurocrine Biosciences Inc
$355M9.2%2.5M+620K (+33%)4 of 8
3
BMRN
Biomarin Pharmaceutical Inc
$332M8.6%5.5M−500K (−8%)7 of 8
4
ARWR
Arrowhead Pharmaceuticals in
$315M8.1%4.8M+3.2M (+206%)4 of 8
5
INSM
Insmed Inc
$311M8.0%2.7M+2.5M (+990%)4 of 8
6
UTHR
United Therapeutics Corp Del
$257M6.7%475K+40K (+9%)3 of 8
7
ASND
Ascendis Pharma A/s
$169M4.4%740K+365K (+97%)2 of 8
8
NRIX
Nurix Therapeutics Inc
$167M4.3%7M−1M (−13%)8 of 8
9
TARS
Tarsus Pharmaceuticals Inc
$160M4.1%2M+984K (+94%)3 of 8
10
ELVN
Enliven Therapeutics Inc
$148M3.8%3.2M−775K (−19%)6 of 8
🔒 53 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
ABT
Abbott Labs
$127M1.4M
AZN
Astrazeneca PLC Ord
$85.3M450K
RVMD
Revolution Medicines Inc
$84.3M450K
BCRX
Biocryst Pharmaceuticals Inc
$83M8.3M
RGEN
Repligen Corp
$54.6M400K

🔒 Free account: see all 20.

Reported value

last 8 quarters
$1.7BQ4 '24
$1.4BQ1 '25
$1.9BQ2 '25
$2.2BQ3 '25
$2.7BQ4 '25
$3.6BQ1 '26
$4.3BQ2 '26
$3.9BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Vestal Point Capital 13F FAQ

What does Vestal Point Capital own?

Vestal Point Capital reported 63 stocks worth $3.9B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ABVX (10.1%), NBIX (9.2%) and BMRN (8.6%). The table above lists every position in the filing (the top 10 without an account).

What did Vestal Point Capital buy and sell in Q3 2026?

Compared with Q2 2026: 15 new positions, 23 added to, 20 trimmed and 20 sold out. New positions include TVTX, RCUS and BBIO. It sold all of ABT, AZN and RVMD.

When will Vestal Point Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Vestal Point Capital's portfolio worth?

The Q3 2026 filing reports $3.9B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.